Valeant Pharma (VRX) Reports Q2 EPS of $1.91

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. FIX
9. TSCO
10. BE

Go back to Valeant Pharma (VRX) Reports Q2 EPS of $1.91

Valeant (VRX) Price Target Reduced at Deutsche Bank

July 31, 2014 3:08 PM EDT

Deutsche Bank maintained a Hold rating on Valeant Pharmaceuticals (NYSE: VRX) and reduced its price target to $128.00 (from $133.00). The change follows its Q2 report. Analyst Gregg Gilbert described results as "ho-hum."

"While EPS of $1.91 came in line with our estimate (helped by lower tax rate), gross margin, operating income, and cash flow came in under our... More

Valeant Pharma (VRX) price drop a buying opportunity, Bill Ackman tells CNBC

July 31, 2014 12:19 PM EDT

Valeant Pharma (NYSE: VRX) price drop a buying opportunity, Bill Ackman tells CNBC. Shares are down nearly 7.6% following results.

... More